Summer Road’s Ocular Therapeutix OCUL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $120M | Buy |
12,208,296
+328,471
| +3% | +$2.98M | 74.46% | 1 |
|
|
2026
Q1 | $101M | Buy |
11,879,825
+771,270
| +7% | +$7.35M | 70.84% | 1 |
|
|
2025
Q4 | $135M | Sell |
11,108,555
-1,471,102
| -12% | -$17.9M | 97.92% | 1 |
|
|
2025
Q3 | $147M | Sell |
12,579,657
-1,307,811
| -9% | -$15.6M | 98.57% | 1 |
|
|
2025
Q2 | $129M | Buy |
13,887,468
+9,450
| +0.1% | +$74K | 98.23% | 1 |
|
|
2025
Q1 | $102M | Buy |
13,878,018
+8,550
| +0.1% | +$65.7K | 98.23% | 1 |
|
|
2024
Q4 | $118M | Sell |
13,869,468
-528,725
| -4% | -$5.16M | 98.61% | 1 |
|
|
2024
Q3 | $125M | Sell |
14,398,193
-487,440
| -3% | -$4.02M | 98.66% | 1 |
|
|
2024
Q2 | $102M | Buy |
14,885,633
+525,000
| +4% | +$3.24M | 98.54% | 1 |
|
|
2024
Q1 | $131M | Buy |
14,360,633
+6,700,083
| +87% | +$47.6M | 100% | 1 |
|
|
2023
Q4 | $34.2M | Buy |
7,660,550
+1,538,461
| +25% | +$4.55M | 100% | 1 |
|
|
2023
Q3 | $19.2M | Hold |
6,122,089
| – | – | 100% | 1 |
|
|
2023
Q2 | $31.6M | Hold |
6,122,089
| – | – | 100% | 1 |
|
|
2023
Q1 | $32.3M | Hold |
6,122,089
| – | – | 100% | 1 |
|
|
2022
Q4 | $17.2M | Buy |
6,122,089
+27,328
| +0.4% | +$90.5K | 100% | 1 |
|
|
2022
Q3 | $25.3M | Buy |
6,094,761
+150,000
| +3% | +$756K | 100% | 1 |
|
|
2022
Q2 | $23.9M | Hold |
5,944,761
| – | – | 100% | 1 |
|
|
2022
Q1 | $29.4M | Buy |
5,944,761
+180,000
| +3% | +$998K | 100% | 1 |
|
|
2021
Q4 | $40.2M | Buy |
5,764,761
+145,900
| +3% | +$1.13M | 100% | 1 |
|
|
2021
Q3 | $56.2M | Hold |
5,618,861
| – | – | 100% | 1 |
|
|
2021
Q2 | $79.7M | Hold |
5,618,861
| – | – | 100% | 1 |
|
|
2021
Q1 | $92.2M | Hold |
5,618,861
| – | – | 100% | 1 |
|
|
2020
Q4 | $116M | Buy |
5,618,861
+437
| +0% | +$6.49K | 100% | 1 |
|
|
2020
Q3 | $42.8M | Hold |
5,618,424
| – | – | 100% | 1 |
|
|
2020
Q2 | $46.8M | Buy |
5,618,424
+363,636
| +7% | +$2.41M | 100% | 1 |
|
|
2020
Q1 | $26M | Buy |
5,254,788
+1,450,000
| +38% | +$7.16M | 99.63% | 1 |
|
|
2019
Q4 | $15M | Hold |
3,804,788
| – | – | 99.32% | 1 |
|
|
2019
Q3 | $11.6M | Hold |
3,804,788
| – | – | 57.21% | 1 |
|
|
2019
Q2 | $16.7M | Hold |
3,804,788
| – | – | 51.37% | 1 |
|
|
2019
Q1 | $15.1M | Buy |
3,804,788
+19,938
| +0.5% | +$80.2K | 43.34% | 1 |
|
|
2018
Q4 | $15.1M | Buy |
3,784,850
+757,362
| +25% | +$4.17M | 62.56% | 1 |
|
|
2018
Q3 | $20.8M | Hold |
3,027,488
| – | – | 68.81% | 1 |
|
|
2018
Q2 | $20.4M | Hold |
3,027,488
| – | – | 67.96% | 1 |
|
|
2018
Q1 | $19.7M | Buy |
+3,027,488
| New | +$17M | 67.84% | 1 |
|
Other funds holding OCUL
DTC
ACA
VA
LGM
Summer Road's OCUL Position: Q2 2026 in Review
Summer Road increased its Ocular Therapeutix (OCUL) stake by 2.8% in Q2 2026, buying an estimated $2.98M and bringing the position to 12,208,296 shares worth $120M. The position accounts for 74.46% of the portfolio, ranked #1.
Summer Road first reported a position in OCUL in Q1 2018 and has held it in 34 quarters since. The position peaked at $147M in Q3 2025. 260 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.
- Summer Road held 12,208,296 shares of Ocular Therapeutix worth $120M as of Q2 2026.
- Summer Road bought 328,471 Ocular Therapeutix shares in Q2 2026, an estimated $2.98M.
- Ocular Therapeutix made up 74.46% of Summer Road's portfolio in Q2 2026, its #1 holding.
- Summer Road first reported a position in Ocular Therapeutix in Q1 2018 and has held it in 34 quarters since.
- Summer Road's Ocular Therapeutix position peaked at $147M in Q3 2025.
- 260 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.
Based on Summer Road's 13F filing for Q2 2026, filed 10 Aug 2026.